poster abstractReplication incompetent retroviral vectors are currently used in phase 1 clinical trials for genetic
therapy of disorders of the blood and the immune system, as vector integration into the genome of
target stem cells provides stable long-term expression of the therapeutic transgene. We have
previously shown that co-localization of the viral particles and the target cells on the recombinant
fibronectin fragment CH-296 enhances the retroviral gene transfer efficiency into primitive
hematopoietic cells including stem cells. Here, we report additional technical details for
improving the gene transfer efficiencies into hematopoietic cell lines, primary human T-cells and
CD34+ cells and demonstrate that CH-296 can be used at least three times without any loss of
efficiency. Finally, we expand the range of viral proteins known to directly bind to fibronectin
CH-296 to the commonly used VSV-G, GaLV and foamyviral (FV) envelope
